STADA's nine-month profit jumps 18%

German generics firm STADA Arzneimittel AG says that its profit for the first nine months of 2008 increased 18% year-on-year to 82.0 million euros ($105.0 million), while earnings per share jumped to 1.40 euros from 1.20 euros.

Group sales rose 13% to 1.23 billion euros, as international revenues increased 18% to 796.3 million euros, contributing 64.6% of group turnover.

Generics, which continues to be the firm's largest core segment, comprising 69.3% of total income, saw sales grow 4% to 854.2 million euros. Turnover of branded products showed an acquisition-related increase of 31% to 273.0 million euros.